We are live on ! Find out more
XENT

Intersect ENT, Inc

Delisted

XENT was delisted on the 12th of May, 2022.

108 hedge funds and large institutions have $373M invested in Intersect ENT, Inc in 2020 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

36% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 33

13% more capital invested

Capital invested by funds: $331M → $373M (+$42.3M)

11% less funds holding

Funds holding: 121108 (-13)

29% less call options, than puts

Call options by funds: $2.05M | Put options by funds: $2.89M

46% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 28

Holders
108
Holders Change
-13
Holders Change %
-10.74%
% of All Funds
2.21%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
15
Increased
45
Reduced
33
Closed
28
Calls
$2.05M
Puts
$2.89M
Net Calls
-$841K
Net Calls Change
-$2.86M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$36.8M +$1.44M +123,355 +5%
DM
2
Deerfield Management
New York
$34.9M -$2.11M -181,388 -7%
UBS Group
3
UBS Group
Switzerland
$29.7M +$37.2K +3,199 +0.1%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$22.6M +$1.04M +89,037 +6%
Vanguard Group
5
Vanguard Group
Pennsylvania
$22.3M +$177K +15,235 +0.9%
Artisan Partners
6
Artisan Partners
Wisconsin
$20.3M +$3.25M +279,513 +23%
FLAM
7
First Light Asset Management
Minnesota
$16.1M -$3.1M -266,279 -18%
PVI
8
Pura Vida Investments
New York
$13.9M +$3.98M +342,509 +50%
Neuberger Berman Group
9
Neuberger Berman Group
New York
$12.7M -$295K -25,394 -3%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$11M -$42.9K -3,689 -0.5%
State Street
11
State Street
Massachusetts
$10.9M +$961K +82,589 +11%
Jennison Associates
12
Jennison Associates
New York
$8.61M -$2.99M -256,580 -29%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$7.97M +$4.84M +415,761 +241%
N
14
Nuveen
North Carolina
$7.75M -$143K -12,289 -2%
BG
15
Bellevue Group
Switzerland
$7.62M +$210K +18,068 +3%
NHAS
16
Novo Holdings A/S
Denmark
$7.56M +$2.19M +187,920 +51%
RSCM
17
Rock Springs Capital Management
Maryland
$6.77M
Geode Capital Management
18
Geode Capital Management
Massachusetts
$6.4M +$271K +23,273 +5%
Northern Trust
19
Northern Trust
Illinois
$6.2M +$316K +27,195 +6%
Invesco
20
Invesco
Georgia
$5.45M +$151K +12,949 +3%
JP Morgan Chase
21
JP Morgan Chase
New York
$5.38M +$675K +58,012 +17%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$4.38M +$831K +71,400 +28%
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
$3.83M +$1.08M +92,758 +49%
Allianz Asset Management
24
Allianz Asset Management
Germany
$3.57M +$3.07M +263,583 New
Assenagon Asset Management
25
Assenagon Asset Management
Luxembourg
$3.5M +$3.01M +258,362 New

XENT Hedge Fund Activity: Q2 2020 in Review

108 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q2 2020, worth a combined $373M — up 13% from $331M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of XENT and 15 opened new positions — a net loss of 13 holders — while 33 trimmed existing stakes and 45 added.

The largest buyer was D.E. Shaw & Co, adding an estimated $4.84M. The largest seller was Polar Capital, cutting an estimated $11M.

  • 108 institutional investors held Intersect ENT, Inc (XENT) as of Q2 2020, down from 121 in Q1 2020.
  • Funds reported $373M of Intersect ENT, Inc stock for Q2 2020, up 13% quarter-over-quarter.
  • 15 funds opened new Intersect ENT, Inc positions in Q2 2020 and 28 closed out, a net change of -13 holders.
  • The largest Intersect ENT, Inc buyer in Q2 2020 was D.E. Shaw & Co, an estimated $4.84M added.
  • The largest Intersect ENT, Inc seller in Q2 2020 was Polar Capital, an estimated $11M sold.

Based on aggregated 13F filings for Q2 2020.